TOP > > Shinya Yamanaka
Shinya Yamanaka 山中 伸弥
Scientists website
As a result of gaining an understanding of cell characteristics, we have made progress in drug discovery research using iPS cells. Using iPS cells originating from amyotrophic lateral sclerosis (ALS) patients, we have discovered seeds for medical treatment. For chronic infantile neurological cutaneous articular syndrome (CINCA), we have succeeded in separating the normal cells from mutated-gene cells in patients' cells using iPS cells, and thereby established methods for developing new treatments and medication.
Bringing iPS Cell Technology from Bench to Bedside
We are seeking to apply iPS cells to identify the mechanism of difficult - to - treat diseases, and establish global standards for various iPS cell related technologies available today to realize re generative medicine.

Applying iPS cell technology to medical research, drug discovery, and regenerative medicine Stem cells are cells that can replicate cells in the body. On the other hand, induced pluripotent stem (iPS) cells are artificially made stem cells with more or less the same ability as embryonic stem (ES) cells made from embryos, and are capable of developing into any cell in the body. iPS cells are expected to be used widely in research because they can avoid ethical concerns such as the destruction of embryos, a problem with ES cells. Everywhere in the world, studies attempting to generate iPS cells from patient skin cells to study the mechanism of diseases and use in drug development are being launched. Once iPS cell research progresses, we should be able to make the cells and tissues required to treat various diseases, and cure diseases that have been difficult to treat. Aiming to apply iPS cells in drug discovery and regenerative medicine, in this project, we will compare the properties of iPS cells generated using various combinations of source tissues and generation methods to identify iPS cells best suited to drug discovery and clinical applications and develop global standards in the field.


Evaluation of different iPS cell generation technologies and establishment of global standards Since the announcement of iPS cells, countries around the world have begun to put effort into developing technology for creating iPS cells. This project aims to conduct comparative analysis on the burgeoning number of iPS cell generation methods, gain an understanding of cell characteristics, carry out GMP-compliant cell preparation, and establish global standards for outstanding iPS cell generation technology in the aspects of quality and safety. We also hope to carry out clinical research on regenerative medicine for various intractable diseases and help encourage new medical industries.


figure